A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum
Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if Disitamab Vedotin combined with Toripalimab works to treat advanced HER2-positive extramammary Paget disease of the scrotum. It will also learn about the safety of this combination. The main questions it aims to answer are: Does this combination reduce tumor volume and delay disease progression? What medical problems do participants have when receving this combination? Participants will: Intravenous using this combination every 3 weeks until disease progression or intolerable adverse reactions occur. Visit the clinic once every 3 weeks for checkups and tests.
Phase:
PHASE2
Details
Lead Sponsor:
Fujian Medical University Union Hospital
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Fujian Provincial Hospital Quanzhou First Hospital Zhangzhou Affiliated Hospital of Fujian Medical University Zhejiang Tumor Hospital